Get Premium Data for Cyber Monday: Up to 55% Off InvestingProCLAIM SALE

Standard Biotools Inc (LAB)

NASDAQ
Currency in USD
1.820
+0.060(+3.41%)
Closed
After Hours
1.780-0.040(-2.198%)
LAB Scorecard
Full Analysis
Management has been aggressively buying back shares
Fair Value
Day's Range
1.7301.840
52 wk Range
1.2103.040
Key Statistics
Edit
Prev. Close
1.76
Open
1.77
Day's Range
1.73-1.84
52 wk Range
1.21-3.04
Volume
872.84K
Average Volume (3m)
1.81M
1-Year Change
-18.75%
Book Value / Share
unlockUnlock
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LAB Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
3.083
Upside
+69.396%
Members' Sentiments
Bearish
Bullish
ProTips
Holds more cash than debt on its balance sheet
Show more

Standard Biotools Inc Company Profile

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Compare LAB to Peers and Sector

Metrics to compare
LAB
Peers
Sector
Relationship
P/E Ratio
−4.0x−4.7x−0.7x
PEG Ratio
−0.11−0.510.00
Price/Book
1.4x2.7x2.6x
Price / LTM Sales
4.3x4.1x3.2x
Upside (Analyst Target)
51.1%26.0%47.0%
Fair Value Upside
Unlock9.7%7.5%Unlock

Analysts' Recommendations

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 3.083

(+69.41% Upside)

FAQ

What Is the Standard Biotools (LAB) Stock Price Today?

The Standard Biotools stock price today is 1.82

What Stock Exchange Does Standard Biotools Trade On?

Standard Biotools is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Standard Biotools?

The stock symbol for Standard Biotools is "LAB."

What Is the Standard Biotools Market Cap?

As of today, Standard Biotools market cap is 677.51M.

What is Standard Biotools Earnings Per Share?

The Standard Biotools EPS is -0.61.

What Is the Next Standard Biotools Earnings Date?

Standard Biotools will release its next earnings report on 11 Feb 2025.

From a Technical Analysis Perspective, Is LAB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.